Panacea Biotec Limited has achieved a favorable outcome in its ongoing tax litigation, with the Income Tax Appellate Tribunal (ITAT) allowing the company's appeal and setting aside a substantial tax demand of ₹9.16 crore for Assessment Year 2020-21. The company disclosed this development through a regulatory filing dated April 30, 2026, in compliance with SEBI listing regulations.

ITAT Order Details

The Income Tax Appellate Tribunal, Delhi, through its order dated April 29, 2026, allowed the appeal filed by Panacea Biotec and set aside the order dated August 14, 2025, issued by the Commissioner of Income Tax (Appeals). The appellate tribunal's decision addresses issues arising from a Rectified Assessment Order dated October 10, 2023, which was passed by the Assessing Officer under sections 143(3) and 154 of the Income Tax Act, 1961.

Background of Tax Dispute

The original tax dispute stemmed from the Assessing Officer's decision to raise a demand of ₹9.16 crore for Assessment Year 2020-21. This demand was based on an addition of ₹3.44 crore under Section 14A of the Income Tax Act, read with Rule 8D of the Income Tax Rules, 1962. The company had challenged this assessment through the appellate process, first approaching the Commissioner of Income Tax (Appeals), and subsequently the Income Tax Appellate Tribunal.

Financial Implications

The ITAT's favorable ruling carries significant positive financial implications for Panacea Biotec. The tribunal's order effectively results in complete deletion of the disallowances of expenses amounting to ₹3.44 crore as well as cancellation of the entire demand of ₹9.16 crore previously raised by the Assessing Officer. This provides substantial financial relief to the pharmaceutical company and removes the contested tax burden from its books.

Regulatory Compliance and Disclosure

Panacea Biotec has disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was made pursuant to Para B of Part A of Schedule III of the SEBI LODR Regulations, ensuring transparency with stakeholders regarding material developments in ongoing litigation matters.

The comprehensive disclosure includes detailed annexure providing all requisite information as per SEBI Master Circular and Industry Standards, demonstrating the company's commitment to regulatory compliance and stakeholder transparency.

Panacea Biotec Limited has reported a fire incident at the Oncology Quality Control Laboratory of its wholly owned subsidiary, Panacea Biotec Pharma Limited (PBPL), located in Baddi, Himachal Pradesh. The incident occurred on April 30, 2026, temporarily disrupting operations at the facility.

Incident Details

The fire broke out on Thursday, April 30, 2026, at approximately 12:23 P.M. due to a short circuit at the Oncology Quality Control Laboratory. The company's internal team successfully controlled the fire within a short timeframe, preventing any escalation of the situation.

Operational Impact

The fire incident has resulted in temporary disruption of operations at the Oncology Facility of PBPL. The company estimates that operations will be affected for a period of 5 to 7 days. Despite the operational disruption, Panacea Biotec has indicated that the incident is not likely to have a material impact on the company's financials.

Insurance Coverage and Recovery Measures

PBPL has confirmed that there is adequate insurance coverage for the affected facility. The company has already made the necessary intimation to the insurance company regarding the incident. PBPL is currently assessing the extent of loss and damage resulting from the fire while taking all necessary and adequate measures to restore operations at the earliest possible time.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided all requisite details as required under the regulations, ensuring full transparency with stakeholders and regulatory authorities about the incident and its potential implications.